Three Nights Without Cannabis Disrupted Sleep. Extended-release Zolpidem Blunted Much of It. | Research

The takeaway

In a small crossover study of daily users, early cannabis abstinence measurably disturbed sleep on polysomnography, and extended-release zolpidem reduced most of those disruptions without next-day impairment.

Readers who want objective data on how early cannabis abstinence affects sleep and what happened when a common hypnotic was tested head-to-head with placebo.

3 nights
length of each abstinence period, during which polysomnography captured objective sleep disruption

What the researchers found

When participants stopped cannabis for three nights and took placebo at bedtime, objective sleep quality dropped. They spent less of their time in bed asleep (lower sleep efficiency) and slept fewer total minutes. It took longer to fall asleep. Sleep architecture shifted, with less Stage 1 and Stage 2 sleep, shorter REM latency, and more time spent in REM. Subjective sleep quality also worsened compared to nights when participants were using cannabis.

During the parallel abstinence period with extended-release zolpidem at bedtime, many of these changes were dampened. Sleep efficiency returned to pre-abstinence levels, and broader architecture disruptions were attenuated. One exception stood out: zolpidem did not shorten sleep latency, so time to fall asleep remained prolonged. Across study nights, zolpidem was not linked to significant side effects or next-day cognitive performance deficits on the tests used.

Why it matters

Sleep disturbance is one of the most common withdrawal symptoms reported by regular cannabis users. This study moved past self-report to measure sleep with polysomnography during early abstinence and tested whether a standard hypnotic changed those signals.

The numbers in context

- Sample: 20 daily cannabis users in a within-subject, placebo-controlled crossover

- Abstinence windows: 3 nights per condition (placebo vs extended-release zolpidem at bedtime)

- Placebo-abstinence vs cannabis use: lower sleep efficiency and total sleep time; longer time to fall asleep; less Stage 1 and Stage 2; shorter REM latency; more time in REM; worse subjective sleep

- Zolpidem during abstinence: sleep efficiency normalized; architecture disruptions attenuated; no change in sleep latency

How the study worked

Within-subject, placebo-controlled crossover. Twenty daily cannabis users alternated between periods of ad libitum cannabis use and short abstinence windows of three days. During one abstinence period they received placebo at bedtime, and during the other they received extended-release zolpidem at bedtime. Each day included overnight polysomnography to quantify sleep stages and efficiency, subjective sleep ratings, and next-day cognitive testing. The abstract does not report dose, setting, or country.

Who was studied

N=20 daily cannabis users, Country not specified

What this study cannot tell us

Small sample (N=20). Only three nights of abstinence per condition, so no insight into longer withdrawal courses. No dose information for zolpidem in the abstract. Cannabis potency, product type, and timing of last use were not reported. Potential order or carryover effects are not detailed. Outcomes were limited to sleep architecture, subjective ratings, and short next-day cognitive tests, not clinical endpoints like craving or return to cannabis use.

How to read the evidence

Rated preliminary: placebo-controlled within-subject crossover with polysomnography supports internal validity, but the sample was small, abstinence windows were brief, and outcomes were surrogate sleep measures rather than longer-term clinical endpoints.

When this study was published

Published in 2011, before today’s higher-potency and more diverse cannabis products became widespread. Withdrawal severity and sleep patterns may differ with current use patterns. The study did not report product types or potencies.

The bigger picture

Objective sleep data matched what many users describe during early abstinence: shorter, more fragmented nights and changes that look like REM rebound. The hypnotic tested here countered part of that pattern and did so without measurable next-day impairment in this small sample. The trial did not track outcomes beyond three nights, so it cannot speak to how long sleep disruption lasts, whether sleep normalizes on its own, or whether altering sleep during withdrawal changes craving, mood, or return-to-use patterns. It also cannot assess uncommon adverse effects or the impact of repeated or longer hypnotic use.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Do these sleep disruptions and their attenuation with zolpidem persist or change beyond three nights of abstinence?
Would improving sleep during early abstinence alter craving, mood, or return-to-use patterns?
How do different hypnotics, doses, or immediate-release formulations compare to extended-release zolpidem in this context?
Are there sex differences or effects in people with baseline insomnia or other sleep disorders?
Do REM changes during cannabis withdrawal relate to next-day mood or cognitive function over longer periods?

Common questions

What changed in sleep during early cannabis withdrawal?

Compared to nights of usual cannabis use, participants had lower sleep efficiency and total sleep time, took longer to fall asleep, entered REM sooner, and spent more time in REM. Subjective sleep quality worsened.

Did extended-release zolpidem help?

It attenuated several sleep architecture changes and brought sleep efficiency back to baseline levels. It did not reduce the longer time to fall asleep seen during abstinence.

Were there next-day problems from zolpidem in this study?

On the measures used, no significant side effects or cognitive performance impairments were detected the following day.

Does this study say anything about relapse or craving?

No. The trial focused on sleep architecture, subjective sleep quality, and short next-day cognitive tests over three nights. It did not measure craving or return-to-use outcomes.

Read the original research

Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal.

Drug and alcohol dependence, 117(1), 38-44

Drug and Alcohol Dependence is a peer-reviewed scientific journal focusing on the biomedical and psychosocial aspects of substance abuse.

View on PubMed ↗Publisher’s paper ↗

Citation

Vandrey, Ryan; Smith, Michael T; McCann, Una D; Budney, Alan J; Curran, Erin M. (2011). Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal.. Drug and alcohol dependence, 117(1), 38-44. https://doi.org/10.1016/j.drugalcdep.2011.01.003